Steve R. Ebbs

Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs et al. · Clinical Cancer Research · 2005 · 347 citations · Full text

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

S R Johnston, Gloria Saccani‐Jotti, I. E. Smith et al. · PubMed · 1995 · 304 citations

Tumor Biology, Breast Oncology, Progesterone Receptor +14

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

Mitch Dowsett, Steve R. Ebbs, J. Michael Dixon et al. · Journal of Clinical Oncology · 2005 · 288 citations · Full text

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

Mitch Dowsett, Catherine Harper‐Wynne, Irene Boeddinghaus et al. · PubMed · 2001 · 173 citations

Her-2 Positivity, Breast Oncology, Estrogen Receptor +16

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs et al. · Clinical Cancer Research · 2006 · 146 citations